Revolution Medicines Files 8-K: Other Events

TL;DR

REVMD filed an 8-K for 'Other Events' - need to see what's up.

AI Summary

On December 2, 2024, Revolution Medicines, Inc. filed an 8-K report. The filing indicates an "Other Events" item, suggesting a significant development not covered by other standard 8-K categories. Specific details regarding the nature of this event, any financial implications, or parties involved are not immediately apparent from the provided header information.

Why It Matters

This filing signals a material event for Revolution Medicines, Inc. that requires immediate disclosure to investors, potentially impacting the company's stock price and future outlook.

Risk Assessment

Risk Level: medium — The 'Other Events' category can encompass a wide range of significant corporate actions, making the specific risk level unclear without further details from the filing's content.

Key Players & Entities

• Revolution Medicines, Inc. (company) — Registrant
• 0001193125-24-268404 (filing_id) — Accession Number
• 20241202 (date) — Filing Date
• 700 Saginaw Drive, Redwood City, CA 94063 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share RVMD The Nasdaq

Filing Documents

• d169582d8k.htm (8-K) — 128KB
• g169582g04a04.jpg (GRAPHIC) — 87KB
• g169582g05a05.jpg (GRAPHIC) — 62KB
• g169582g06a06.jpg (GRAPHIC) — 63KB
• g169582g08a08.jpg (GRAPHIC) — 92KB
• g169582g09a09.jpg (GRAPHIC) — 62KB
• g169582g10a10.jpg (GRAPHIC) — 61KB
• g169582g12a12.jpg (GRAPHIC) — 79KB
• 0001193125-24-268404.txt ( ) — 1416KB
• rvmdw-20241202.xsd (EX-101.SCH) — 4KB
• rvmdw-20241202_def.xml (EX-101.DEF) — 13KB
• rvmdw-20241202_lab.xml (EX-101.LAB) — 21KB
• rvmdw-20241202_pre.xml (EX-101.PRE) — 14KB
• d169582d8k_htm.xml (XML) — 6KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this report that are not historical facts may be considered "forward-looking statements," including, without limitation, statements regarding the potential advantages, including potential safety, tolerability, efficacy, and durability, of RMC-6236 and RMC-6291, alone or in combination with other therapies; the Company's plans to initiate a global, randomized Phase 3 trial comparing RMC-6236 against docetaxel in patients with RAS-mutated NSCLC; the Company's plans for further development involving RAS(ON) inhibitors, including RAS(ON) inhibitor doublets and other combinations; the ability of the Company's compounds to address a broad range of tumor types or be used in earlier lines of therapy; and the Company's ability to develop a chemotherapy-sparing treatment option. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect" and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the Company's development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation: risks and uncertainties inherent in the drug development process, in performing clinical studies, and in the process of designing and conducting clinical trials; risks that the results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results; the regulatory approval processes; the timing of regulatory filings; the challenges associated with manufacturing drug products; the Company's ability to successf

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVOLUTION MEDICINES, INC. Date: December 2, 2024 By: /s/ Mark A. Goldsmith Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR